학술논문
Caspofungin for the treatment of candidaemia in patients with haematological malignancies.
Document Type
Article
Author
Source
Subject
*DRUG therapy
*HEMATOLOGY
*INTERNAL medicine
*PHARMACOLOGY
*NEUTROPENIA
*
*
*
*
Language
ISSN
1198-743X
Abstract
Clin Microbiol Infect 2010; 16: 298–301 This study was prospectively conducted in 11 haematology divisions over a 2-year period to evaluate the efficacy of caspofungin in 24 neutropenic patients with haematological malignancies (HM) and candidaemia. These patients had received chemotherapy for HM and were neutropenic (PNN < 0.5 × 109/L) for a median of 12 days (2–41) before candidaemia. The patients received caspofungin for a median duration of 12 days (range 6–26), obtaining a favourable overall response of 58%. At 30 days, 11 patients had died (46%); candidaemia was responsible for mortality in six patients (25%). These results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as it is in non-haematological subgroups. [ABSTRACT FROM AUTHOR]